Humacyte to present new clinical data on bioengineered vascular grafts at VEITHsymposium

Humacyte to present new clinical data on bioengineered vascular grafts at VEITHsymposium
Humacyte shares vessel data at VEITH

Humacyte announced it will present new data on its acellular tissue engineered vessels at the VEITHsymposium. The presentation, led by Dr. Rishi Kundi, is scheduled for November 18 during Session 3 on lower extremity arterial procedures.

The company aims to highlight the potential clinical applications of its bioengineered human vessels for patient care, signaling ongoing progress in regenerative medicine and vascular surgery.

Earlier, Humacyte reported a 44 percent increase in hospitals ordering Symvess during the third quarter, indicating growing demand among surgeons for the company's vascular products. The company also recently presented interim Phase 3 results of its acellular tissue engineered vessels for hemodialysis access in women at Kidney Week during the V012 trial. These developments highlight Humacyte's ongoing efforts in advancing vascular solutions for clinical use.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.